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Increased levels of transforming growth factor-b in HIV-asso- The pathological features of HIVAN are those of the
ciated nephropathy. collapsing variant of focal and segmental glomeruloscle-
Background. Human immunodeficiency virus-associated rosis (some investigators would also include the lesionnephropathy (HIVAN) is a renal disease of unknown patho-
of “classic” focal and segmental glomerulosclerosis) withgenesis. Recent evidence suggests that the fibrogenic cytokine
regularly occurring acute tubular necrosis, tubular dila-transforming growth factor-b (TGF-b) might be involved. We
hypothesized that overproduction of TGF-b in the kidney tion, and interstitial infiltrates of T cells, and widespread
might be involved in the pathogenesis of HIVAN. ultrastructural abnormalities, including cytoplasmic tu-
Methods. The mRNA and protein expression of TGF-b iso- buloreticular structures [2, 3]. Initially described in intra-forms, TGF-b1, TGF-b2, and TGFb3, deposition of matrix
venous drug abusers with acquired immunodeficiencyproteins induced by TGF-b, and levels of HIV Tat protein were
syndrome (AIDS) in 1984 [4], it is now known to affectstudied in HIVAN. Controls included normal and diseased
kidneys from HIV-positive and -negative patients. The ability patients with all manifestations of HIV infection, includ-
of Tat to induce production of TGF-b and matrix proteins was ing clinically silent infections, and to occur in individuals
also studied in human mesangial cells. who contracted HIV by any mode of transmission. TheResults. Normal kidneys, thin basement membrane ne-
vast majority of patients in the United States withphropathy, and minimal change disease were negative for the
HIVAN are African Americans, and the time from pre-three TGF-b isoforms and Tat. In HIVAN, levels of TGF-b
isoforms and Tat were significantly increased, along with the sentation to end-stage renal disease may be as short as
expression of TGF-b mRNA and deposition of matrix proteins a few months [5].
stimulated by TGF-b. Increased levels of TGF-b isoforms, but Although the pathogenesis of HIVAN is not known,not Tat, were also found in other glomerular diseases character-
recent evidence suggests that the fibrogenic cytokineized by matrix accumulation. HIV infection, in the absence of
transforming growth factor-b (TGF-b) might be in-HIVAN, was not associated with an increase in TGF-b or Tat
expression. Tat stimulated the expression and production of volved. HIV-transgenic mice develop a renal syndrome
TGF-b1 and matrix proteins by human mesangial cells. that resembles HIVAN, and their kidneys contain
Conclusions. Our findings suggest that overproduction of increased levels of TGF-b mRNA and protein [6–8].TGF-b is involved in the pathogenesis of HIVAN.
Peripheral blood mononuclear cells obtained from HIV-
infected humans produce and secrete TGF-b, and ele-
vated plasma and tissue levels of TGF-b have been re-Human immunodeficiency virus-associated nephropa-
ported in patients infected with HIV [9–13]. In additionthy (HIVAN) is a renal disease characterized clinically
to being fibrogenic, TGF-b has been shown to have aby heavy proteinuria often without nephritic syndrome,
cell-specific regulatory action on HIV replication [14],progressive renal insufficiency, and enlarged kidneys [1].
and is a potent regulator and suppressor of the immune
system [14–17]. Thus, overproduction of TGF-b may
contribute to immunosuppression in HIV-infected pa-Key words: TGF-b, HIV nephropathy, kidney disease, glomer-
ulonephritis, fibrosis, matrix accumulation, Tat. tients and in AIDS [10, 11] as well as to the development
of HIVAN.Received for publication March 24, 1998
The fibrogenic actions of TGF-b have been implicatedand in revised form September 3, 1998
Accepted for publication September 11, 1998 in the development of pathological tissue fibrosis in a
number of organs, especially the kidney [18–21]. These 1999 by the International Society of Nephrology
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actions include the ability to strongly induce extracellular METHODS
matrix deposition by simultaneously (1) stimulating syn- Kidney samples
thesis of matrix, (2) inhibiting matrix degradation by Fifty-seven needle biopsy specimens of human kidney
decreasing protease synthesis, and increasing protease tissue remaining after diagnostic evaluation were ob-
inhibitors, and (3) altering matrix receptors, integrins, tained, following Institutional Review Board approval,
to allow for increased binding and deposition of compo- from Cedars-Sinai Medical Center (Los Angeles, CA,
nents of extracellular matrix [21]. In experimental forms USA), Hamamatsu University Hospital (Hamamatsu,
of glomerular disease and in human glomerulopathies, Japan), and Teikyo University Hospital (Tokyo, Japan).
in which pathological extracellular matrix accumulation Kidney samples were obtained from 19 patients with
is a feature, glomerular and tubulointerstitial expression HIVAN. As HIV-positive disease controls, we examined
of TGF-b, as evaluated by immunohistochemical and seven cases of primary glomerular disease obtained from
molecular biological techniques, is greatly increased [19, HIV-infected patients, including two with IgA nephropa-
20, 22]. Thus, TGF-b has the biological potential to pro- thy, one with membranous nephropathy, one with mem-
duce the fibrosis that, along with tubular cell damage, branoproliferative glomerulonephritis, two with acute
glomerular collapse and interstitial edema, causes the glomerulonephritis, and one with focal and segmental
rapid loss of renal function in HIVAN. glomerulosclerosis. One histologically normal kidney
In HIV-infected patients, renal parenchymal cells may sample obtained from a HIV-infected patient because
be infected by HIV and perhaps may trigger TGF-b of trauma was also examined. As HIV-negative disease
production, or lymphocytes or macrophages infected controls, we studied kidney samples from 31 patients
with HIV might infiltrate the kidney and locally produce with primary glomerular disease, including five with thin
TGF-b. HIV gene products released from HIV-infected basement membrane disease, seven with minimal change
renal cells might also induce TGF-b production in the disease, 10 with focal and segmental glomerulosclerosis,
kidney [8]. HIV produces a number of gene products five with IgA nephropathy, one with membranoprolifer-
that regulate its complex expression. One of these is the ative glomerulonephritis, two with pauci immune cres-
transactivator of transcription or Tat protein. Tat may centic glomerulonephritis, and one with membranous
also alter host function by directly transactivating cellu- nephropathy. Seven normal kidney samples were used
lar gene transcription or influencing cytokine production. as control tissues. All samples included at least four
Tat is taken up by cells in culture and has been shown glomeruli. The racial composition of the patients was as
to stimulate production of TGF-b by macrophages [23] follows: all HIVAN patients were African American;
and cells derived from the central nervous system [24]. the HIV-positive disease controls included three whites,
HIV tat gene transfer to the central nervous system of three Hispanics, and one African American. The HIV-
mice has been shown to stimulate TGF-b production [25]. positive normal kidney was from a white person, and
Given the complex interactions between HIV infec- the HIV-negative normal kidneys were also from whites
tion, Tat, and TGF-b, we hypothesized that the deposi- except for one Asian. The remaining 31 HIV-negative
tion or production of Tat and the overproduction of disease controls were 40% white, 30% Asian, 15% Afri-
TGF-b in the kidneys of HIV-infected patients might be can American, and 15% Hispanic. The pathologist who
involved in the pathogenesis of HIVAN. To test this provided the renal biopsy tissue was aware of the diagno-
hypothesis, we examined the levels of both protein and sis; however, the evaluator of the immunofluorescence
mRNA of the TGF-b isoforms, TGF-b1, TGF-b2, and and in situ hybridization studies was blinded to the origin
TGFb3, and Tat protein in renal biopsy specimens with of the tissue and the diagnosis.
HIVAN. For comparison, we included other glomerulo-
Antibodiespathies and normal kidneys from patients with and with-
out HIV infection. We also studied the effects of Tat Primary antibodies to the three isoforms of TGF-b,
protein on the production of TGF-b1 and matrix proteins -b1, -b2, and -b3, were prepared by immunizing rabbits
in cultured human mesangial cells. with synthetic peptides of each isoform as described else-
Our results show that striking amounts of TGF-b are where [26]. Peptides of amino acid residues 4–19 were
present in human kidneys in HIVAN, along with in- used to raise TGF-b1 and -b2 antibodies, and residues
creased amounts of Tat. When Tat was added to cultured 9–20 were used for TGF-b3. The antibodies were purified
human mesangial cells, it stimulated the production of by affinity chromatography using the respective immu-
active TGF-b1 and matrix proteins. These results sup- nogen peptides. Western blot analysis demonstrated that
port our hypothesis and implicate TGF-b in the patho- each purified antibody reacted only with the appropriate
genesis of HIVAN. Furthermore, they suggest that the TGF-b isoform [26]. Mouse monoclonal antibody to the
use of antagonists of TGF-b or possibly Tat might be human fibronectin splice variant, EDA1 (extra domain
A positive) and human plasminogen activator inhibitor,beneficial in patients with HIVAN.
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type 1 (PAI-1) were obtained from Accurate Chemical (Vanderbilt University, Nashville, TN, USA) [27]. Anti-
sense and sense cRNA riboprobes were generated afterand Scientific Corporation (Westbury, NY, USA) and
American Diagnostica Inc. (Greenwich, CT, USA), re- digestion with restriction enzymes (Takara Shuzo, Otsu,
Japan), Hind III and Eco RI for TGF-b1, Eco RI andspectively. Fluorescein isothiocyanate (FITC)-conjugated
donkey F (ab9)2 antirabbit antibody and FITC-conju- Xho I for TGF-b2, and Hind III and Xho I for TGF-b3,
respectively. Riboprobes were labeled with digoxigeningated rat F (ab9)2 antimouse IgG antibody were used as
secondary antibodies (Jackson Immunoresearch, West using the DIG RNA-labeling kit (Boehringer Mannheim
Biochemica, Mannheim, Germany). Sections were rehy-Grove, PA, USA). Nonimmune rabbit or mouse sera
were used in place of the primary antibody as controls. drated, digested with 10 mg/ml of proteinase K (Boeh-
ringer Mannheim), postfixed in 4% paraformaldehyde,
Immunohistological examination treated with 0.2 n HCl, and then acetylated. Ten ng/ml
Four-micrometer serial cryostat sections were fixed of digoxigenin-labeled riboprobes in the hybridization
in acetone, washed in 0.15 m phosphate-buffered saline solution containing 50% deionized formamide, 0.3 m
(PBS), pH 7.4, and incubated with the primary antibod- NaCl, 10 mm Tris HCl, pH 8.0, 5 mm ethylenediaminetet-
ies. After washing with PBS, the sections were incubated raacetic acid, 10 mm NaH2PO4, 0.2 mg/ml salmon sperm
with the appropriate secondary antibodies conjugated DNA (Sigma, St. Louis, MO, USA), 0.1 mg/ml yeast
with FITC. After washing, the slides were mounted with transfer RNA (Takara), 1 3 Denhardt’s solution, and
cover glasses using Bartels buffered glycerol mounting 10% dextran sulfate were added to the slides and were
medium FA (Baxter, Deerfield, IL, USA). incubated for 18 hours at 508C. The slides were washed
The intensity of intraglomerular staining of TGF-b1, sequentially with 5 3 SSC and 2 3 SSC containing 50%
TGF-b2, TGF-b3, fibronectin EDA1, and PAI-1 was formamide at 508C and treated with 20 mg/ml of RNase A
evaluated according to the following 0 to 4 scale in coded (Boehringer Mannheim) for 30 minutes at 378C. Washing
sections observed at magnification 3400: 0 5 no staining; was then continued once with 2 3 SSC and twice with
1 5 weak and spotty intraglomerular staining; 2 5 mod- 0.2 3 SSC at 508C. Slides were washed with buffer 1
erate and segmental intraglomerular staining; 3 5 mod- (0.1 m Tris-HCl and 0.15 m NaCl, pH 7.5) and were
erately strong and segmental or moderate but diffuse incubated with buffer 1 containing 10% normal sheep
(involving more than 50%) intraglomerular staining; and serum and 1.5% blocking reagent (Boehringer Mann-
4 5 strong and diffuse intraglomerular staining. The heim) for 60 minutes at room temperature. The sections
intensity of tubulointerstitial staining of TGF-b1, were incubated with alkaline phosphatase-conjugated
TGF-b2, TGF-b3, fibronectin EDA1, and PAI-1 in the sheep antidigoxigenin antibody (Boehringer Mannheim)
cortical areas was evaluated according to the following 0 in buffer 1 containing 1% normal sheep serum for 60
to 4 scale in the coded sections observed at magnification minutes. The slides were washed twice with buffer 1 and
3250: 0 5 no staining; 1 5 deposition that involves less were rinsed in buffer 3 (0.1 m Tris-HCl, 0.1 m NaCl, 0.05
than 10% of the cortical area; 2 5 involving 10% to m MgCl2, pH 9.5). The color solution was added, which
30%; 3 5 involving 30% to 50%; and 4 5 involving consisted of 45 ml 4-nitro blue tetrazolium chloride, 35 ml
more than 50%. All glomeruli and 20 randomly selected 5-bromo-4-chloro-3-indoylphosphate (Boehringer Mann-
cortical tubulointerstitial areas per sample were evalu- heim), and 2.5 mg levamisole (Sigma) in 10 ml buffer 3.
ated with the observer being blinded to the diagnosis. The color reaction was developed in a dark box and was
The mean values of the glomerular and tubulointerstitial stopped with 0.01 m Tris-HCl, 1 mm ethylenediaminetet-
scores were calculated. raacetic acid, pH 8.0. Slides were rinsed in distilled water
and were covered with aqueous mounting medium.
In situ hybridization
Immunohistological demonstration of TatIn situ hybridization to examine the expression of
TGF-b1, TGF-b2, and TGF-b3 mRNAs was carried out The expression of Tat protein was examined immuno-
as described elsewhere [22] on 13 kidney tissues, includ- histochemically in 31 kidney specimens is which there
ing three samples of HIVAN, one of histologically nor- was sufficient tissue available as summarized in Table 1.
mal kidney obtained from an HIV-infected patient, and Mouse monoclonal anti-Tat antibody was provided by
from HIV-negative patients. There were four samples Dr. J. Karn of the Medical Research Council (London,
each of focal and segmental glomerulosclerosis and mini- UK). The specificity of the antibody had been confirmed
mal change disease and one normal kidney. by enzyme-linked immunosorbent assay (ELISA) in
which the antibody was shown to bind to recombinantBriefly, 4 mm serial sections of 4% paraformalde-
hyde-fixed, paraffin-embedded renal tissues were placed Tat protein [28]. Four micrometer sections of 4% para-
formaldehyde-fixed, paraffin-embedded renal tissueson 3-aminopropyl-triethoxysilane-coated slides. The
cDNA plasmids of murine TGF-b1, pmTGF-b1-A, mu- were placed on 3-aminopropyl-triethoxysilane-coated
slides, deparaffinized by xylene, rehydrated by gradedrine TGF-b2, pmTGF-b2-9A, and murine TGF-b3,
pmTGF-b3-11b were kindly provided by Dr. H.L. Moses alcohol, and washed in PBS. The sections were treated
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Table 1. Summary of Tat protein immunoreactivity by ultracentrifugation of the lysate through a cesium
chloride gradient and ethanol precipitation. RNA con-Staining intensity of Tat protein
centration was determined using spectrophotometricN Glomeruli Tubules Interstitial Cells
readings at an absorbance of 260 nm. RNA blotting
HIV-positive
was carried out as described elsewhere [29]. A mouseglomerular
diseases TGF-b1 cDNA probe (plasmid MUI5), a rat procollagen
HIVAN 10 111 111 11 a1 cDNA (plasmid pa 1R1), and a human biglycan
IgA 2 6 6a 2 cDNA probe (plasmid P16) were kindly provided byMN 1 2 a 2
Drs. R. Derynck et al [30], D. Rowe et al [31], and L.W.AGN 1 2 a 2
Normal 1 2 a 2 Fisher et al [32], respectively. A rat glyceraldehyde-3-
HIV-negative phosphate dehydrogenase (GAPDH) cDNA probe was
glomerular a generous gift from Drs. P. Kondaiah and M.B. Sporn
diseases [33]. Autoradiography films were scanned by a laser den-FGS 4 2 a 2
sitometer (LKB, Bromma, Sweden). The density ofIgA 5 2 a 2
MPGN 1 2 a 2 bands for GAPDH mRNA was used to control for the
CresGN 2 2 a 2 differences in the total amount of mRNA loaded ontoMC 3 2 a 2
each gel lane.MN 1 2 a 2
Abbreviations are: HIVAN, HIV-associated nephropathy; IgA, IgA nephrop-
ELISA for TGF-b activity in cultured humanathy; MN, membranous nephropathy; AGN, acute glomerulonephritis; FGS,
focal and segmental glomerulosclerosis; MPGN, membranoproliferative glomer- mesangial cells
ulonephritis; CresGM, pauci immune crescentic glomerulonephritis; MC, mini-
mal change disease. An ELISA for activated total human TGF-b1 (R&D
a Weak staining of Tat in some normal tissues may reflect expression of as Systems, Minneapolis, MN, USA) was carried out ac-yet unknown endogenous retroviral (-like) elements or molecular mimicry of
conformational epitopes, like an RGD sequence, shared by viral and host mole- cording to the manufacturer’s instructions, using human
cules [28]. TGF-b1 to construct a standard curve as previously de-
scribed [34]. This ELISA measures only total TGF-b1
and shows less than 1% cross-reactivity with TGF-b2 or
TGF-b3 and has a detection limit of 50 pg/ml. For analy-with 3% hydrogen peroxide to block endogenous peroxi-
sis, cell culture supernatant samples were first activateddase activity. After incubation for 10 minutes at room
with 1 n HCl and were then neutralized with 1.2 n NaOH/temperature in 10% normal donkey serum, the sections
0.5 m Hepes. Two hundred microliters of each activated
were incubated with mouse monoclonal anti-Tat anti- sample were assayed in duplicate, with pairs showing no
body. They were incubated with biotin-conjugated don- more than a 10% variation. The mean values are given
key antimouse IgG (Chemicon International Inc., Teme- for each pair.
cula, CA, USA) and were then streptavidin conjugated
with peroxidase, and finally, the reaction products were Statistical analysis
visualized using color solution consisted of 20 mg 393- Differences between groups in immunofluorescence
diaminobenzidine, 40 mg sodium azide, and 35 ml of scoring of TGF-b isoforms and matrix components were
30% hydrogen peroxide in 100 ml of 0.05 m Tris-HCl analyzed by analysis of variance. Differences in TGF-b
buffer, pH 7.6. A washing step was carried out between ELISA scores were subjected to correlation analysis.
each incubation.
RESULTSTat stimulation of cultured human mesangial cells
Immunohistological localization of TGF-b1, TGF-b2,Human mesangial cells were maintained in RPMI 1640
and TGF-b3 proteinsmedium (Sigma) supplemented with 18% fetal bovine
serum (Hyclone Laboratories, Logan, UT, USA), 100 Striking increases in the immunoreactivity of all three
U/ml penicillin, 100 mg/ml streptomycin, 0.1 U/ml insulin, TGF-b isoforms, greater than in any other glomerular
and 25 mm Hepes buffer at 378C in a 5% CO2 incubator. disease, were noted in HIVAN (Figs. 1 and 2). The
Confluent human mesangial cells, passage four, were glomeruli and tubules, as well as infiltrating mononuclear
incubated with serum-free medium for 24 hours. Then, cells, parietal epithelial cells, and some interstitial arter-
0 to 1000 ng/ml of human recombinant Tat protein (In- ies were positively stained. Immunoreactivity for all
tracel Corp., Cambridge, MA, USA) was added. After three TGF-b isoforms was both intracellular and associ-
48-hours incubation, the supernatants were harvested ated with the pathological matrix in the glomeruli and
for analysis of the culture samples, or the cells were tubulointerstitium. In the glomeruli, we were unable to
washed twice with 0.01 m PBS, pH 7.4, in preparation identify the specific cell types responsible for the in-
for RNA extraction. Total RNA was prepared by lysis creased expression of TGF-b. A lesser increase in stain-
ing of the three TGF-b isoforms was observed in controlof cells in guanidine isothiocyanate solution followed
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Fig. 1. Immunofluorescence micrographs of TGF-b1 (a, d), TGF-b2 (b, e), and TGF-b3 (c, f) in serial sections of HIVAN (a–c) and normal
control (d–f). In HIVAN, strong staining of the three TGF-b isoforms was observed in the sclerosing glomeruli, parietal epithelial cells, and the
periglomerular and tubulointerstitial lesions with interstitial mononuclear cell infiltration and matrix deposition (magnification 3210).
tissues with abnormal glomerular and tubulointerstitial In all samples, the intensity of TGF-b staining corre-
lated with the type of glomerular disease and not thematrix accumulation from HIV-positive patients with
other primary glomerular diseases (Fig. 2). In HIV-nega- HIV status of the patient, and was greatest in HIVAN
(Fig. 2). In normal kidneys and in disease controls intive patients, there was increased expression of the three
which matrix accumulation is not a feature (thin base-TGF-b isoforms in all of the samples of primary glomeru-
ment membrane disease and minimal change disease),lar disease with matrix accumulation, including IgA ne-
no increases in staining of the three TGF-b isoformsphropathy, membranoproliferative glomerulonephritis,
were found (Fig. 2).pauci immune crescentic glomerulonephritis, membra-
nous nephropathy, and focal and segmental glomerulo-
In situ hybridization of TGF-b1, TGF-b2, andsclerosis, as we have reported previously [22]. However,
TGF-b3 mRNAsthe strongest TGF-b staining in an HIV-negative primary
glomerular disease was found in focal and segmental Increased expression of TGF-b mRNA of all three
isoforms in the glomeruli and tubulointerstitium was ob-glomerulosclerosis (Fig. 2).
Yamamoto et al: TGF-b in HIV-associated nephropathy584
Deposition of fibronectin EDA1 and PAI-1
To show that the TGF-b found in diseased glomeruli
is biologically active, the tissue was examined for the
presence of fibronectin EDA1 and PAI-1. These two
matrix molecules are strongly induced by TGF-b, are
found in healing wounds, but are minimally present in
normal tissue. In HIVAN, significantly increased deposi-
tion of fibronectin EDA1 and PAI-1 was noted in the
abnormal glomeruli and in periglomerular and tubuloin-
terstitial lesions in which mononuclear cell infiltration
and increased interstitial matrix deposition were seen
(Figs. 4 and 5). Although increased deposition of fibro-
nectin EDA1 and PAI-1 was also observed in other
glomerulopathies from both HIV-positive and HIV-neg-
ative patients, the deposition of fibronectin EDA1 was
significantly more in the glomeruli and tubulointer-
stitium in HIVAN patients (Fig. 5). In normal controls,
trace deposits of fibronectin EDA1 and PAI-1 were
observed in the glomeruli and interstitium (Figs. 4 and
5). Similar immunostaining was seen in minimal change
disease and thin basement membrane disease (Fig. 5).
Immunostaining of Tat protein in HIVAN
Strong staining of Tat protein was noted in the glomer-
uli and tubules of kidneys from patients with HIVAN
(Fig. 6 and Table 1). Some infiltrating mononuclear cells
in the tubulointerstitium were also positively stained.Fig. 2. Glomerular (a) and tubulointerstitial (b) immunofluorescence
staining scores of TGF-b1 ( ), TGF-b2 ( ), and TGF-b3 ( ) in No Tat was present in tubular casts. In other primary
HIV-negative, normal control (NC), thin basement membrane disease glomerular diseases occurring in HIV-infected patients
(TBMD), minimal change disease (MC), focal and segmental glomeru-
and a histologically normal kidney obtained from anlosclerosis (FSG), and immune complex glomerulonephritis in HIV-
infected patients (ICGN, HIV1) and HIV-associated nephropathy (HI- HIV-infected patient, the glomeruli and tubulointersti-
VAN). The error bars represent se. *P , 0.01 versus NC, TBMD, and tial areas were negative for Tat; however, there was
MC; P , 0.05 versus FGS.
occasional weak staining in some tubules (Fig. 6).
No Tat staining was found in the kidney in primary
glomerular diseases occurring in HIV-negative patients,
except for rare tubules that showed faint staining (Fig.
6 d–f and Table 1). Interstitial mononuclear cells wereserved in HIVAN and in disease controls. However,
uniformly negative for Tat. No Tat was found in normalthe intensity of mRNA expression for the three TGF-b
control kidneys. Control staining without anti-Tat anti-isoforms was much greater in HIVAN (Fig. 3 a–c, g–i).
body was negative in all sections (results not shown).In HIVAN, remarkably strong mRNA expression of the
three TGF-b isoforms was also noted in a large number Human mesangial cells stimulated by Tat
of mononuclear cells in periglomerular and tubulointer-
Mesangial cells are a major source of the pathologicalstitial areas (Fig. 3 d–f), parietal epithelial cells, and
matrix that accumulates in glomeruli in progressive glo-
tubular cells surrounded by interstitial mononuclear
merular diseases. We tested whether Tat protein can
cells. stimulate the production of TGF-b1 and two other ma-
In normal kidney, weak expression of TGF-b isoforms’ trix proteins induced by TGF-b1, type I collagen, and
mRNAs was found in a few glomerular cells, some pari- biglycan when added to cultures of human mesangial
etal epithelial cells, some tubular cells, a few interstitial cells. As shown in Figure 7, there is a stepwise increase
cells, and interstitial arteries (Fig. 3 j–l). Similarly, weak in mRNA levels of TGF-b1, type I collagen, and biglycan
expression of the three TGF-b isoforms’ mRNAs was as increasing concentrations of Tat are added. When
observed in minimal change disease and a histologically stimulated by Tat, the mesangial cells also secreted in-
normal kidney obtained from an HIV-infected patient. creased amounts of total TGF-b1, as measured by
Labeling of the control sense probes was not increased ELISA, in conditioned medium treated to convert all
TGF-b1 to the active form (Fig. 8).over the background (results not shown).
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Fig. 3. In situ hybridization demonstrating
the expression of TGF-b1 mRNA (a, d, g,
j), TGF-b2 mRNA (b, e, h, k), and TGF-b3
mRNA (c, f, i, l) in serial sections of HIVAN
(a–f) and in HIV-negative focal and segmental
glomerulosclerosis (g–i) and normal control
(j–l). Increased expression of TGF-b mRNA
of all three isoforms was observed in the glo-
meruli and tubulointerstitium of HIVAN
(a–c) and focal and segmental glomeruloscle-
rosis (g–i). However, the intensity of mRNA
expression for the three TGF-b isoforms was
much greater in HIVAN. A large number of
interstitial infiltrative mononuclear cells were
also strongly expressing the three TGF-b iso-
forms’ mRNAs in HIVAN (d–f; magnification
of a–c and g–l 3135 and d–f 5 3100).
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Fig. 4. Immunofluorescence micrographs of fibronectin EDA1 (a, c) and PAI-1 (b, d) in serial sections of HIVAN (a, b) and normal control (c,
d). Remarkably strong intraglomerular and tubulointerstitial staining of fibronectin EDA1 and PAI-1 was observed in HIVAN (magnification
3230).
DISCUSSION significantly correlated with the degree of pathological
matrix accumulation in the glomeruli and tubulointerstit-Our purpose in conducting this study was to test the
ium [21]. Recently, Bo´di et al reported similar findingshypothesis that overproduction of TGF-b could be a
in diverse human glomerulopathies, as well as in casescause of the rapidly progressive fibrosis that character-
of HIVAN [38].izes HIVAN. TGF-b has been shown by us, as well as
In humans, TGF-b is present in three isoformsother investigators, to be a potent fibrogenic cytokine in
(TGF-b1, TGF-b2, and TGF-b3) that have similar effectswhich overproduction is the likely cause of a number
on extracellular matrix protein synthesis when evaluatedof experimental and human fibrotic disorders [21]. The
in vitro. In our study, we examined the levels of the threekidney is especially susceptible to TGF-b’s fibrogenic
TGF-b proteins by immunostaining and the mRNAs byeffects. Injection of recombinant TGF-b1 or transfer of
in situ hybridization in order not to overlook the possibil-the TGF-b1 gene into the kidneys of normal rats leads
ity of differential involvement of one or more of theto glomerulosclerosis within days [35]. Mice that overex-
isoforms. We also included detection of two proteinspress the TGF-b1 transgene in their livers have elevated
as markers of TGF-b’s biological activity. Fibronectinplasma levels of TGF-b and die of renal failure [36, 37].
EDA1 is an isoform of fibronectin that is thought toIn addition, we have reported increased TGF-b expres-
play a role in the assembly and deposition of new matrixsion in a spectrum of human glomerular diseases, includ-
ing glomerulonephritis and diabetic nephropathy, which [39]. It is specifically induced by TGF-b in cultured cells
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tion of matrix proteins, fibronectin EDA1, and PAI-1
was also greatly increased in the same areas as TGF-b.
As sensitive markers of TGF-b’s fibrogenic actions [22],
the finding of these proteins indicates that TGF-b ex-
pressed in the glomeruli and tubulointerstitium is acting
to increase matrix accumulation.
As controls in this study, we examined normal kidney
tissue from both HIV-positive and HIV-negative individ-
uals and from a number of HIV-positive and HIV-nega-
tive individuals who had a variety of forms of progressive
primary glomerular diseases. As additional controls, we
included minimal change disease and thin basement
membrane disease, two glomerular diseases that do not
progress to fibrosis or renal failure. In both of these
diseases, there was no increase in TGF-b staining com-
pared with normal control. The intensity of expression
of the three TGF-b proteins and mRNAs was much
greater in HIVAN than in any of the other glomerular
diseases. Normal kidney from both HIV-infected and
noninfected individuals was also similar in showing only
negative or trace amounts of TGF-b staining.
In HIVAN, the HIV regulatory protein Tat might be
one stimulus for increased production of the fibrogenic
cytokine TGF-b in the kidney. Tat is an 86–115 amino
acid polypeptide translated from multiply spliced RNA
species containing two coding exons. Tat binds a trans-
Fig. 5. Glomerular (a) and tubulointerstitial (b) immunofluorescence activation responsive element in the viral RNA and in-
staining scores of fibronectin EDA1 ( ) and PAI-1 ( ) in HIV- creases the production of full-length viral mRNA tran-
negative, normal control (NC), thin basement membrane disease
scripts [8]. Recently, Tat has been shown to stimulate(TBMD), minimal change disease (MC), focal and segmental glomeru-
losclerosis (FGS), and immune complex glomerulopathy in HIV- TGF-b expression and matrix deposition in glial cells
infected patients (ICGN, HIV1) and HIV-associated nephropathy [24, 43] and marrow macrophages [23], and Tat-mediated
(HIVAN). The error bars represent se. *P , 0.01 versus NC, TBMD,
induction of TGF-b expression has been suggested toand MC; P , 0.01 vs. FGS and #P , 0.05 versus ICGN, HIV 1 0.
play a role in the development of neurologic and bone
marrow disorders in AIDS patients [23, 25]. Several pre-
vious studies demonstrated that Tat is released from
HIV-infected cells as a biologically active protein, and
and in tissues following injury and is not present in nor- has a capacity to be taken up by the uninfected cells and
mal kidney [19]. The second protein is PAI-1, which is a exert its biological activity [44, 45]. Extracellular Tat
potent inhibitor of the plasmin protease system. Plasmin protein has also been implicated in the development or
plays a major role in degradation and turnover of extra- progression of Kaposi’s sarcoma in HIV-infected pa-
cellular matrix and especially the glomerular mesangial tients [45, 46].
matrix [40, 41]. PAI-1 deposited into the matrix prevents The epitopes of HIV regulatory proteins Tat, Nef, and
the generation of plasmin and thus protects the matrix Rev have been shown to be weakly expressed in normal
from degradation. The strong stimulation of PAI-1 by human tissues and to be strongly expressed in HIV-
TGF-b is the basis for a sensitive bioassay for specific infected tissues [28]. The finding of HIV epitopes in
measurement of TGF-b in biological samples [42]. normal tissues is unlikely to be due to nonspecific reactiv-
In cases of HIVAN, we found striking increases in the ity of the antibodies because the antibodies used were
levels of TGF-b proteins and mRNAs of the three shown to bind to the respective recombinant proteins,
TGF-b isoforms in the glomeruli and tubules. A number and extensive controls were negative. The presence of
of mononuclear cells in the periglomerular and tubuloin- HIV-regulatory protein epitopes in normal tissue may
terstitial lesions were also strongly positive. The intensity reflect expression of as yet unknown endogenous retrovi-
of TGF-b staining in HIVAN was significantly greater ral (-like) elements or molecular mimicry of conforma-
than what we had previously reported in other fibrotic tional epitopes, such as an RGD sequence, that is shared
glomerular diseases, including rapidly progressive glo- in viral and host molecules [28].
Using an anti-Tat antibody well characterized by oth-merulonephritis and diabetic nephropathy. The deposi-
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Fig. 6. Tat-staining of HIVAN (a), HIV-positive membranous nephropathy (b), histologically normal kidney obtained from a patient infected
with HIV (c), and HIV-negative focal and segmental glomerulosclerosis (d), membranous nephropathy (e), and minimal change disease (f).
Remarkably strong staining of Tat was noted in the glomerular, tubular, and infiltrative interstitial mononuclear cells in HIVAN (a). No tubular
casts were stained positively. In HIV-positive membranous nephropathy (b) and a histologically normal kidney obtained from a HIV-infected
patient (c), the tubules were weakly stained. No Tat staining was found in the glomeruli or interstitial mononuclear cells in HIV-negative primary
glomerular diseases (d, e, f); however, some tubules were stained faintly (magnification 3240).
ers, we examined the level of Tat protein in kidney sam- staining in some tubules in a few cases of primary glomer-
ular disease may be due to the factors cited earlier hereples from HIVAN patients and controls. Tat was found
in the glomerular, tubular, and interstitial mononuclear concerning the weak expression of HIV-regulatory pro-
tein epitopes in some normal tissues. We also tested thecells in HIVAN but not in tubular casts. In contrast, Tat
staining was largely negative in the kidneys of HIV- ability of Tat to stimulate the production of TGF-b and
matrix proteins in vitro by human mesangial cells. Wenegative or HIV-infected patients with other glomerular
diseases and normal kidneys. The presence of faint Tat found that Tat stimulated expression of TGF-b1 mRNA
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Fig. 7. Northern blot data showing the expression of TGF-b1 (A), type
I collagen (B), biglycan (C), and GAPDH (D) mRNAs in human
mesangial cells incubated for 48 hours with 0 (lane 1), 25 (lane 2), 100
(lane 3), and 500 ng/ml (lane 4) of Tat protein. Graphical presentation
of densitometric analysis of gels shown in A–C corrected for GAPDH
shown in D. (E) A stepwise increase in expression of TGF-b1 ( ),
type I collagen ( ), and biglycan ( ) mRNAs was noted in human
mesangial cells stimulated by Tat protein.
and secretion of TGF-b1 protein and induced expression ments that the development of HIVAN required the
presence of the HIV transgene in the kidney. Thus, HI-of matrix components, type I collagen, and biglycan.
Although we and others have demonstrated the pres- VAN in this mouse model is intrinsic to the kidney and
is not due to a systemic “milieu” caused by HIV infection.ence of HIV-genomic materials in human kidney tissues
in HIVAN [47, 48], a major controversy in the pathogen- Our findings in human HIVAN support the same conclu-
sion. The presence of systemic HIV infection did notesis of HIVAN is whether the disease is caused by direct
HIV infection in the kidney or whether it is due to sys- increase levels of Tat or TGF-b in either normal or
diseased kidney over what was found in HIV-negativetemic activation of cytokines. Bruggeman et al’s recent
study strongly suggests that direct HIV infection of renal kidneys. In contrast, in HIVAN we found elevated levels
of Tat and TGF-b in the kidney. This result suggests thatparenchymal cells is required for the development of
HIVAN [49]. These investigators studied HIV-trans- in addition to HIV infection, something in the kidney
is required to render it vulnerable to development ofgenic mice and showed in elegant transplantation experi-
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mel reported stimulatory action of TGF-b on the expres-
sion of the HIV gene in human mesangial cells trans-
fected with HIV-LTR gene [56]. Thus, the stimulatory
action of TGF-b on HIV replication together with the
positive regulatory action of Tat on TGF-b expression
and HIV replication may lead to a vicious cycle of accel-
erating virus replication, TGF-b expression, and matrix
accumulation that may play a pathogenic role in HIVAN.
These potential synergistic interactions suggest that, in
addition to blocking angiotensin II, targeting the actions
of TGF-b or Tat might also prove useful in patients with
HIVAN.
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